GANX News and Press, Gain Therapeutics Inc. From 12/07/21

BETHESDA, Md., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lyso...

BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders,...

David Einhorn's 13F stock portfolio value decreased from $1.59B to $1.49B this quarter. Greenlight increased The ODP Group, LivaNova plc, and Sonos while reducing Concentrix and AerCap Holdings. The largest three positions are at ~44% of the portfolio. As of Q3 2021, the overall p...

Gain Therapeutics (NASDAQ:GANX): Q3 GAAP EPS of -$0.39 misses by $0.03. Revenue of $27.34K (+308.7% Y/Y) Press Release For further details see: Gain Therapeutics EPS misses by $0.03

Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF’s Parkinson's Disease Therapeutics Conference --- Appoints Matthias Alder as Chief Operating Officer and Appoints 5 Members to ...

BETHESDA, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lyso...

Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels with transport to the lysosomes in iPSC dopaminergic neurons Results presented at Michael J. Fox Foundation’s Thera...

In-Person Dates: November 16 th -17 th Virtual Dates: November 18 th -19 th BETHESDA, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology c...

- The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Webinars - - Society of Neuroscience 50th Anniversary Meeting – BETHESDA, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the &#x...

Gain Therapeutics has a market cap of just $84m. The biotech is developing small molecules to treat rare genetic diseases. The company uses a proprietary drug discovery engine, SEE-Tx, which targets allosteric binding sites, and misfolded proteins - approaches previously validated eit...